The Company has a resource-efficient structure, operating through an extensive network of research, development and manufacturing subcontractors to develop drug candidates through clinical Phase I/II. Clavis Pharma presently has 22 employees and more than 200 external collaborators world wide. External collaborators include front line research institutes and universities such as National Institutes of Health (NIH) and National Cancer Institute (NCI) and The European Organisation for Research and Treatment of Cancer (EORTC).